Australian case-control study of the efficacy of quadrivalent human papillomavirus vaccine to prevent cervical abnormalities.
Phase of Trial: Phase IV
Latest Information Update: 16 Apr 2014
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Uterine cervical diseases
- Focus Therapeutic Use
- 16 Apr 2014 New trial record
- 04 Mar 2014 Results published in the BMJ online ahead of print.